Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antitubercular Agents

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases. The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organization (WHO) in 2014. However, due to the lack of evidence on the use of delamanid in the paediatric populations, these interim policy recommendations were limited to adult MDR-TB patients under very strict conditions. In view of recent data on the use of delamanid in children diagnosed with MDR-TB, WHO convened an independent, multidisciplinary, international expert panel to assess new data and develop an addendum to the 2014 interim guidance on delamanid, with specific recommendations to paediatric MDR-TB patients. Based on the assessment of this evidence and recommendations from the expert panel, the WHO now recommends that delamanid may be added to the WHO-recommended longer regimen in children and adolescents (6 - 17 years).

Antitubercular agents.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In this dissertation we aim to find a new pediatric galenic formulation for the treatment of tuberculosis. We incorporate the four main tuberculostatic drugs (RMP, INH, EMB and PZA) in one single formulation, which is indispensable worldwide. We have continued our work to find suitable forms for ambulatory treatment as well as for the treatment in hospital. The four compounds are analysed in order to develop the most adequate formulation for toddlers, infected with tuberculosis. We have determined two possible suspensions to be further developed. Both suspensions have been tested. In this dissertation the results are analysed for further comparison Ce mémoire a pour objectif de trouver une nouvelle formulation galénique pédiatrique pour le traitement de la tuberculose. On rassemble les quatre principaux antituberculeux (RMP, INH, EMB et PZA) en une seule formulation indispensable en Belgique et dans le monde entier. On a réfléchi à trouver aussi bien une forme pour le milieu ambulatoire mais aussi pour le milieu hospitalier. Les quatre substances actives sont analysées afin de trouver une formulation adéquate pour les jeunes enfants atteints de la tuberculose. Deux suspensions possibles à réaliser ont été trouvées, elles sont testées et les résultats sont analysés afin de les comparer.

Tuberculosis --- Child --- Antitubercular Agents

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Carcinogens. --- Antitubercular agents --- Toxicology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"An estimated 8.8 million people fell ill with tuberculosis (TB) in 2010 and 1.4 million died from the disease. Although antibiotics to treat TB were developed in the 1950s and are effective against a majority of TB cases, resistance to these antibiotics has emerged over the years, resulting in the growing spread of multidrug-resistant (MDR) TB. Due to challenges in timely and accurate diagnosis of drug-resistant TB, length and tolerability of treatment regimens, and expense of second-line anti-TB drugs, effectively controlling the disease requires complex public health interventions. The IOM Forum on Drug Discovery, Development, and Translation held three international workshops to gather information from local experts around the world on the threat of drug resistant TB and how the challenges it presents can be met. Workshops were held in South Africa and Russia in 2010. The third workshop was held April 18-19, 2011, in New Delhi, India, in collaboration with the Indian National Science Academy and the Indian Council of Medical Research. The aim of the workshop was to highlight key challenges to controlling the spread of drug-resistant strains of TB in India and to discuss strategies for advancing and integrating local and international efforts to prevent and treat drug-resistant TB. This document summarizes the workshop."--Publisher's description.

Multidrug-resistant tuberculosis. --- Antitubercular agents.